Search for a command to run...
Objectives: This randomised controlled trial aimed to assess the efficacy of Atosiban in women undergoing frozen embryo transfer. The specific objectives were to assess the clinical pregnancy rate (PR), implantation rate (IR), biochemical PR and first-trimester miscarriage rate. Material and Methods: The study was conducted at Akanksha in vitro fertilisation (IVF) Centre, New Delhi, from 28 December 2024 to 28 May 2025. A total of 100 women aged 23–40 years undergoing an frozen embryo transfer (FET) cycle were included in the study. Other inclusion criteria are body mass index (BMI) < 30 kg/m 2 , normal uterus on 2D ultrasonography, endometrial thickness ≥ 7 mm on the day of starting progesterone, and at least two good-quality embryos - blastocyst (4AA, 4AB, 4BA, 3AA) transferred. Uterine factors like Ashermann’s syndrome, space-occupying lesions like adenomyosis, fibroids and recurrent implantation failure were excluded from the study. Patients who underwent FET cycles were categorised into two groups: Group A (50 patients)— patients who underwent FET after administration of Atosiban; Group B (50 patients)—patients who underwent FET without prior administration of Atosiban, hence acting as controls. The randomisation of patients was done by a computer-based programme into two groups. A baseline scan was done on Day 2/Day 3. Endometrial preparation was done by sequential incremental administration of oral oestradiol until endometrial thickness was ≥7 mm, followed by oestradiol combined with injectable progesterone as luteal phase support, P + 5 days, where P stands for progesterone (P + 5 refers to 5 days of administration of progesterone). Atosiban IV bolus of 6.75 mg was administered 30 minutes before embryo transfer. Frozen embryo transfer was done in both groups, in which two good-quality blastocysts (4AA, 4AB, 4BA, 3AA) were transferred. A urine pregnancy test or serum beta-human chorionic gonadotrophin (HCG) levels were done 14 days after FET. In case of a positive pregnancy test, the patient was followed up at 6–7 weeks of gestation to assess the pregnancy outcome. In case of a viable pregnancy, the patient was followed up at 11–12 weeks of gestation. Results: Baseline characteristics of both the study groups—age, duration of infertility, S.Antimullerian hormone (AMH), antral follice count (AFC), S.Estradiol—were similar. Group A patients in whom Atosiban was given prior to embryo transfer demonstrated a statistically significantly higher clinical PR as compared to Group B patients without Atosiban (58 vs. 38, p < 0.05). Group A patients demonstrated a higher IR as compared to Group B (33.33 vs. 23.80, p < 0.12), and the biochemical PR was also higher in Group A patients as compared to Group B patients without Atosiban (20 vs. 14, p < 0.42), but the differences were not statistically significant. The first-trimester miscarriage rate was lower in Group A with Atosiban as compared to Group B without Atosiban (17.24 vs. 21.05, p < 1); however, the difference was statistically not significant. Conclusion: The administration of Atosiban before embryo transfer in women has led to an increase in the clinical PR, thus increasing the success rate of the assisted reproductive technology (ART) cycle.